Go to the list of all blogs
Arthur Evans's Avatar
published in Blogs
Sep 02, 2026
Why Is MongoDB (MDB) Stock Down -11.20% Today?

Why Is MongoDB (MDB) Stock Down -11.20% Today?

Key Takeaways

  • MDB shares fell roughly 11.2% in Wednesday's session to about $385.60, extending a sharp post-earnings sell-off from the prior close of $434.21.
  • The decline was earnings-driven: MongoDB beat estimates and raised full-year guidance, yet investors focused on softer-than-hoped cloud momentum.
  • Core cloud platform Atlas grew about 29% year over year for the fifth consecutive quarter, failing to show the acceleration the market was pricing in.
  • Third-quarter guidance implied a growth deceleration to roughly 20–21%, a letdown for a stock trading at a premium valuation.
  • The move came after a roughly 20–30% run-up into the print, leaving little room for error and triggering profit-taking.
  • Traders are now watching whether AI-related workloads can re-accelerate Atlas growth in the back half of fiscal 2027.

Opening Summary

MongoDB, Inc. (MDB), a leading developer-data platform best known for its document-oriented database and the fully managed Atlas cloud service, saw its shares plunge in Wednesday's trading. The stock fell approximately 11.2%, trading near $385.60, down from the prior completed session's close of $434.21. The move confirmed a decisive sell-off sparked by the company's fiscal 2027 second-quarter earnings report, which topped headline expectations but left investors disappointed by the trajectory of its flagship cloud business and near-term guidance.

Earnings Beat and Raised Guidance Failed to Impress

At first glance, MongoDB's results looked strong. Revenue for the quarter ended July 31 rose 30% year over year to $771.8 million, comfortably above the consensus of roughly $735 million, marking the company's fastest top-line growth in several years. Adjusted earnings per share came in at $1.90, up 90% from the prior year and well ahead of the roughly $1.61 analysts expected. Management also raised its full-year fiscal 2027 outlook, lifting revenue guidance to approximately $2.99 billion to $3.03 billion and adjusted EPS guidance to $6.39 to $6.58.

Despite the beat-and-raise quarter, the market reaction was sharply negative. The company had entered the report with elevated expectations after a strong rally, and the results did not clear the higher bar investors had set around its cloud growth and AI-driven acceleration.

Atlas Growth: The Core Disappointment

The central catalyst behind the sell-off was Atlas, MongoDB's cloud database-as-a-service platform and the primary driver of its long-term growth story. Atlas revenue grew about 29% year over year — the same approximate rate for the fifth consecutive quarter. While healthy in absolute terms, the figure did not show the re-acceleration that many investors had anticipated, particularly given the company's push to position Atlas as a foundational layer for AI applications.

Some market participants had privately modeled Atlas growth of 30.5% to 31% heading into the report. When growth merely held steady at roughly 29%, the lack of upside momentum became the focal point. With the stock having run up sharply ahead of earnings, "in line" cloud growth was treated as a disappointment, underscoring how demanding the valuation had become.

Softer Third-Quarter Guidance

Compounding the concern was the company's third-quarter outlook. MongoDB guided to revenue of $756 million to $761 million and adjusted EPS of $1.57 to $1.61, figures that still edged above consensus but implied year-over-year revenue growth decelerating to roughly 20–21%. Coming off a 30% growth quarter, that step-down reinforced fears that the company's expansion is normalizing even as its valuation implies sustained premium growth.

The valuation itself added to the pressure. Even after the decline, MongoDB traded at a multiple many investors found difficult to justify against a mid-20% growth profile, leaving the shares vulnerable to any sign of slowing momentum.

Market Context and Trading Activity

The sell-off in MDB was company-specific rather than a product of broad market weakness. Major equity indexes were little changed on Wednesday, indicating that the move was driven almost entirely by MongoDB's own results and guidance. Trading volume was elevated relative to typical levels as investors repositioned following the earnings release.

The decline also reflected a broader, persistent narrative weighing on enterprise software names: the concern that AI disruption could pressure demand for traditional SaaS and database offerings. MongoDB's quarter did not provide the clear evidence of AI-driven consumption acceleration that bulls were seeking, leaving the shares exposed to profit-taking after a multi-week rally toward recent highs.

What Comes Next for MDB

Looking ahead, investors will focus on whether Atlas can break out of its roughly 29% growth band and demonstrate measurable acceleration from AI-related workloads in the second half of fiscal 2027. Management pointed to strength in core enterprise workloads and "early momentum" with AI use cases, but the market will demand tangible proof that these opportunities translate into faster cloud consumption.

Key items to watch include the next quarterly report, customer and billings trends, remaining performance obligations, and any signals on AI-native customer adoption. Risks remain, including competitive pressure from larger database and cloud rivals, valuation sensitivity to any growth deceleration, and the broader uncertainty around how quickly AI spending flows through to MongoDB's platform. The company's fundamentals remain solid — record customer additions, expanding margins, and a raised full-year outlook — but investor sentiment will hinge on whether growth can re-accelerate.

Trending AI Robots

For traders seeking a systematic, data-driven edge in volatile markets, Tickeron's Trending AI Robots page offers a curated view of its strongest-performing AI trading bots. Tickeron provides hundreds of AI-powered trading bots covering thousands of tickers, but only the top performers under current market conditions are featured in this section. These bots vary by strategy, timeframe, performance metrics, and the symbols they trade, allowing users to explore approaches that align with their goals. Explore the Trending AI Robots to see which automated strategies are leading today.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations

Related Ticker: MDB

Contributor

Financial writer and active order flow futures trader with a focus on fundamental analysis, macroeconomic factors, and equity research. I make in-depth blogs on stocks and ETFs, bridging the gap between raw market data and real-world trading decisions.


MDB in +2.13% Uptrend, advancing for three consecutive days on October 05, 2026

Moving higher for three straight days is viewed as a bullish sign. Keep an eye on this stock for future growth. Considering data from situations where MDB advanced for three days, in 236 of 301 cases, the price rose further within the following month. The odds of a continued upward trend are 78%.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 45 of 60 cases where MDB's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 75%.

Bearish Trend Analysis

The Momentum Indicator moved below the 0 level on September 28, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on MDB as a result. In 67 of 86 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 78%.

The Moving Average Convergence Divergence Histogram (MACD) for MDB turned negative on September 28, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 43 similar instances when the indicator turned negative. In 34 of the 43 cases the stock turned lower in the days that followed. This puts the odds of success at 79%.

MDB moved below its 50-day moving average on September 28, 2026 date and that indicates a change from an upward trend to a downward trend.

The 10-day moving average for MDB crossed bearishly below the 50-day moving average on October 01, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 11 of 16 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 69%.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where MDB declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 79%.

MDB broke above its upper Bollinger Band on September 22, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

The Aroon Indicator for MDB entered a downward trend on October 05, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Fundamental Analysis (Ratings)

The Tickeron Seasonality Score of 35 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.

The Tickeron Price Growth Rating for this company is 44 (best 1 - 100 worst), indicating steady price growth. MDB’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron PE Growth Rating for this company is 67 (best 1 - 100 worst), pointing to slightly better than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron SMR rating for this company is 88 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Valuation Rating of 93 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (9.050) is normal, around the industry mean (18.522). P/E Ratio (471.380) is within average values for comparable stocks, (158.311). Projected Growth (PEG Ratio) (1.654) is also within normal values, averaging (3.648). Dividend Yield (0.000) settles around the average of (0.004) among similar stocks. P/S Ratio (11.025) is also within normal values, averaging (104.490).

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. MDB’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 91, placing this stock worse than average.

Notable companies

The most notable companies in this group are Microsoft Corp (NASDAQ:MSFT), Oracle Corp (NYSE:ORCL), Palo Alto Networks Inc (NASDAQ:PANW), Crowdstrike Holdings Inc (NASDAQ:CRWD), Twilio (NYSE:TWLO), Block Inc (NYSE:XYZ), NetApp (NASDAQ:NTAP), Okta (NASDAQ:OKTA), Zscaler (NASDAQ:ZS), MongoDB (NASDAQ:MDB).

Industry description

Computer communications industry develops technology that allows computing devices to exchange data with each other using connections/data links between nodes. Common types of computer network include Cloud (IAN), Internet, Wide (WAN, Local (LAN)/Wireless(WLAN) etc. The industry is an ever-more important part of technology, and is set to become even bigger as the Internet of Things (IoT) rapidly forays into the various aspects of our lives. Cisco Systems, Inc., Palo Alto Networks, Inc. and Arista Networks, Inc., Fortinet, Inc. are some of the major computer communications companies.

Market Cap

The average market capitalization across the Computer Communications Industry is 35.56B. The market cap for tickers in the group ranges from 48.8K to 3.78T. MSFT holds the highest valuation in this group at 3.78T. The lowest valued company is WMHI at 48.8K.

High and low price notable news

The average weekly price growth across all stocks in the Computer Communications Industry was 1%. For the same Industry, the average monthly price growth was -4%, and the average quarterly price growth was 21%. BIRD experienced the highest price growth at 46%, while VERI experienced the biggest fall at -43%.

Volume

The average weekly volume growth across all stocks in the Computer Communications Industry was -1%. For the same stocks of the Industry, the average monthly volume growth was -27% and the average quarterly volume growth was -28%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 47
P/E Growth Rating: 70
Price Growth Rating: 57
SMR Rating: 78
Profit Risk Rating: 91
Seasonality Score: 3 (-100 ... +100)
View a ticker or compare two or three
MDB
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
A.I.Advisor
published price charts
A.I. Advisor
published General Information

General Information

a developer of MongoDB database

Industry ComputerCommunications

Industry
Packaged Software
Address
1633 Broadway
Phone
+1 646 727-4092
Employees
5636
Web
https://www.mongodb.com
Interact to see
Advertisement
I've been following ANTX, a biopharmaceutical company based in Menlo Park, California, that develops novel small molecule therapeutics from its proprietary boron chemistry platform. The focus is on underserved areas like infectious diseases, with the lead candidate epetraborole advancing in Phase 3 trials for non-tuberculous mycobacterial (NTM) lung disease and acute melioidosis. The pipeline also includes AN2-502998 for chronic Chagas disease in preclinical stages, along with programs in oncology.
Tilly's, Inc. (TLYS) operates as a specialty retailer specializing in casual apparel, footwear, accessories, and hardgoods aimed at young men, women, boys, and girls. The company focuses on branded fashion inspired by action sports, surf, and skate culture, offering products like tops, bottoms, swimwear, backpacks, hats, and sunglasses from well-known brands such as Vans and Hurley. With approximately 223 stores in malls and lifestyle centers, complemented by e-commerce through www.tillys.com, Tilly's effectively combines physical and digital sales channels.
Aemetis, Inc. (AMTX) is a renewable natural gas and renewable fuels company focused on developing and commercializing low- and negative-carbon intensity products that replace petroleum-based fuels. The company operates through segments including California Ethanol, California Dairy Renewable Natural Gas, and India Biodiesel. Its core business model centers on converting agricultural waste—such as dairy manure into biogas and corn/wood waste into ethanol—into high-value biofuels like renewable natural gas (RNG), ethanol, biodiesel, and sustainable aviation fuel precursors.
Silvaco Group, Inc. (SVCO) provides technology computer-aided design (TCAD) software, electronic design automation (EDA) software, and semiconductor intellectual property (SIP) solutions. The company helps semiconductor and photonics firms design, simulate, and optimize processes from atomic-level modeling to complex system-on-chip (SoC) development. Its business centers on licensing software tools and IP blocks, along with engineering services, targeting high-growth areas like AI, power devices, automotive, foundries, and 5G/6G mobile.
UBXG stock surged +79% over the last 30 days, driven by heightened trading volume and positive market sentiment amid broader technology sector trends. Over the past quarter, the stock rose +61%, reflecting recovery from earlier lows near its 52-week bottom.
CVGI stock surged approximately +89% over the last 30 days, driven by strong Q4 2025 earnings beat on revenue and positive 2026 guidance. Over the past quarter, shares rose about +126%, reflecting improved profitability, debt reduction, and a key partnership announcement.
SAFX stock surged +104% over the past 30 days, driven by positive updates on a $10 million capital raise and merger progress. Over the past quarter, the stock rose +44%, reflecting recovery from lows amid renewable energy sector interest and strategic developments.
LONA stock surged +80% over the past 30 days, driven by positive analyst upgrades, executive appointments, and full-year financial updates highlighting pipeline progress. Over the past quarter, shares rose +48%, reflecting improved investor sentiment in biotech amid clinical advancements.
Lifetime Brands (LCUT) stock surged +77% over the last 30 days, driven by a strong Q4 earnings beat and a Zacks Rank #1 (Strong Buy) upgrade that reflects an improved earnings outlook. Over the past quarter, shares rose +48%, supported by profitability gains despite softer sales, with adjusted EBITDA reaching $50.8 million for full-year 2025.
CURV stock surged approximately +73% over the last 30 days, driven primarily by a positive reaction to Q4 and fiscal 2025 earnings that beat expectations on EPS and revenue. Over the past quarter, the stock is up around +55%, reflecting recovery from lows near $1 amid ongoing store optimization and sub-brand launches
Blaize Holdings, Inc. (BZAI) focuses on artificial intelligence (AI)-enabled edge computing solutions, offering programmable AI processors and platforms for verticals such as smart cities, defense, retail, and enterprise markets. The company's core revolves around hardware like the Graph Streaming Processor (GSP) AI accelerator, compute cards, and software tools including Blaize AI Studio—a no-code/low-code environment for deploying AI models without source code expertise. Based in El Dorado Hills, California, and founded in 2010, it went public through a merger in early 2025.
Comstock Holding Companies, Inc. (CHCI) operates as an asset manager, developer, and operator of mixed-use and transit-oriented properties, mainly in the greater Washington, D.C. metropolitan area. The company targets high-growth urban and suburban markets, overseeing a portfolio that spans residential, commercial, hospitality, and parking assets near key metro stations. Its asset-light, fee-based model delivers recurring revenue through property management, leasing, development services, and asset recapitalization for institutional investors, family offices, and governments.
ORIC Pharmaceuticals shares are down approximately 21% in premarket trading on April 1, 2026, from a prior session close of approximately $12.19, placing the premarket price near $9.63. The primary catalyst is the after-market release of Phase 1b dose optimization data for rinzimetostat (ORIC-944) on March 31, alongside the selection of 400 mg once daily as the recommended Phase 3 dose for the Himalayas-1 registrational trial.
Shares of Target Hospitality Corp. (Nasdaq: TH) surged approximately 38% during Wednesday's trading session, climbing from a prior close of $9.28 to approximately $12.81. The primary catalyst is the company's announcement of a landmark multi-year lease and services agreement worth over $550 million with a top-five global hyperscaler to build and operate a data center workforce community in North Texas.
Shares of Turning Point Brands (TPB) are falling sharply intraday on April 1, 2026, shedding approximately 15% from their prior session close of roughly $87.41, placing the stock near $74.30. The primary catalyst is broad investor risk-off selling tied to mounting trade-policy uncertainty ahead of President Trump's sweeping tariff announcements scheduled for April 2 — a day the administration has branded "Liberation Day".
Shares of Philip Morris International fell approximately 8% during intraday trading on April 1, 2026, dropping from a prior close of $165.34 to around $152.11. A sharp, broad-based market selloff — amplified by renewed trade policy tensions — is acting as the primary macro catalyst behind the decline.
WDC shares surged approximately +10% in Wednesday's session, advancing to approximately $296–$297 from a prior close near $269.82 on March 31, 2026. The primary catalyst is a major analyst upgrade: Bernstein raised its rating on Western Digital from Market Perform to Outperform and dramatically doubled its price target to $340 from $170.
I've been following CG Oncology, Inc. (CGON), a late-stage clinical biopharmaceutical company dedicated to developing and commercializing cretostimogene grenadenorepvec. This investigational oncolytic immunotherapy aims to serve as a bladder-sparing therapeutic for patients with non-muscle invasive bladder cancer (NMIBC). The company's focus remains on pushing this intravesical therapy through Phase 3 trials to address high unmet needs in BCG-unresponsive and intermediate-risk NMIBC, where treatments like BCG frequently fall short. In the broader biotech landscape, CG Oncology stands out with cretostimogene's encouraging durability and tolerability, which could position it as a foundational therapy. From what I see, these solid fundamentals—bolstered by strong clinical data and regulatory steps—have directly supported the recent stock price gains amid positive trial developments.
From what I see, Home Depot (HD) remains the world's largest home improvement retailer, operating over 2,300 stores across North America with a broad selection of products for construction, renovation, and maintenance. The company blends big-box retail with an expanding e-commerce platform and tailored services for professional contractors, drawing revenue from both do-it-yourself (DIY) consumers and do-it-for-me (DIFM) pros. In a competitive landscape against players like Lowe's, HD maintains dominance through its scale, efficient supply chain, and strong loyalty programs. Much of its performance ties directly to the housing market—home sales, remodeling, and repairs—which explains the recent pressure on the stock from subdued activity and high mortgage rates limiting turnover and major projects.
GE Aerospace (GE) stock declined -12% over the past 30 days, falling from around $333 to $293, amid profit-taking after record highs near $348. Over the past quarter, the stock is down -8%, reflecting post-earnings selloff despite strong Q4 2025 results with 20% revenue growth.
Why Is MongoDB (MDB) Stock Down -11.20% Today?